About Divi's Laboratories Limited (DIVISLAB)
Divi's Laboratories Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Hyderabad, India. DIVISLAB has been publicly traded since 2003, giving it 23+ years of trading history.
Divi's Laboratories Limited (DIVISLAB) has been publicly traded since 2003, making it a 23-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in Hyderabad, India and employs approximately 10,542 people. With a market capitalization of $1.6 trillion, DIVISLAB is one of the largest publicly traded companies.
DIVISLAB trades on the Indian stock exchanges (NSE/BSE) and is classified as a mega-cap-cap stock with a market capitalization of approximately $1.6 trillion. The company employs approximately 10,542 people worldwide.
Key Statistics
- Current Price
- ₹6,071.00
- Market Cap
- ₹1.61T
- 52-Week High
- ₹7,071.50
- 52-Week Low
- ₹4,955.00
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
DIVISLAB Investment Performance
DIVISLAB has declined 5.0% year-to-date in 2026. Over the past 5 years, a $1,000 investment in DIVISLAB would have grown to $1,681, representing a 68.1% total return. Since its IPO in 2003, a $1,000 investment would now be worth $833,669.
₹1,000 Invested in Divi's Laboratories Limited (DIVISLAB)
How much would ₹1,000 invested in DIVISLAB be worth today?
What would ₹1,000 invested in DIVISLAB 1 year ago be worth today?
A ₹1,000 investment in Divi's Laboratories Limited (DIVISLAB) in 2025 would be worth ₹1,093 as of May 2026, representing a +9.3% total return.
What would ₹1,000 invested in DIVISLAB 3 years ago be worth today?
A ₹1,000 investment in Divi's Laboratories Limited (DIVISLAB) in 2023 would be worth ₹2,133 as of May 2026, representing a +113.3% total return.
What would ₹1,000 invested in DIVISLAB 5 years ago be worth today?
A ₹1,000 investment in Divi's Laboratories Limited (DIVISLAB) in 2021 would be worth ₹1,681 as of May 2026, representing a +68.1% total return.
What would ₹1,000 invested in DIVISLAB 10 years ago be worth today?
A ₹1,000 investment in Divi's Laboratories Limited (DIVISLAB) in 2016 would be worth ₹5,646 as of May 2026, representing a +464.6% total return.
What would ₹1,000 invested in DIVISLAB at IPO be worth today?
A ₹1,000 investment in Divi's Laboratories Limited (DIVISLAB) at IPO would be worth ₹833,669 as of May 2026, representing a +83266.9% total return.
Monthly Returns Heatmap
Over the past 23+ years (276 months), Divi's Laboratories Limited (DIVISLAB) has averaged a monthly return of +3.02% with a median return of +2.90%. The stock had 170 positive months (62%) and 106 negative months (38%). The best month in DIVISLAB's history was June 2003 with a +48.7% return, while the worst was January 2009 at -33.7%. Historically, April tends to be the strongest month (averaging +7.4%), and January the weakest (-5.6%).
DIVISLAB's longest winning streak was 9 consecutive months of gains, while its longest losing streak was 5 consecutive months of losses. The best full year was 2007 with a cumulative return of +131.4%, and the worst was 2016 at -27.4%.
Annual Returns
Over 23 years of trading history, Divi's Laboratories Limited (DIVISLAB) has delivered an average annual return of +29.85% with a median return of +21.62%. The compound annual growth rate (CAGR) is +21.80%. The stock posted gains in 17 years (74%) and losses in 6 years (26%).
DIVISLAB's best year was 2007 with a +207.99% gain, while the worst was 2016 at -31.44%. The longest streak of consecutive positive years was 5, and the longest losing streak was 1 years. DIVISLAB achieved double-digit gains (10%+) in 15 years. It suffered double-digit losses in 4 years.
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -5.03% | ₹6,392.50 | ₹6,071.00 |
| 2025 | +5.29% | ₹6,071.16 | ₹6,392.50 |
| 2024 | +57.18% | ₹3,862.50 | ₹6,071.16 |
| 2023 | +15.30% | ₹3,349.95 | ₹3,862.50 |
| 2022 | -26.48% | ₹4,556.63 | ₹3,349.95 |
| 2021 | +22.27% | ₹3,726.79 | ₹4,556.63 |
| 2020 | +109.70% | ₹1,777.23 | ₹3,726.79 |
| 2019 | +25.81% | ₹1,412.59 | ₹1,777.23 |
| 2018 | +36.03% | ₹1,038.41 | ₹1,412.59 |
| 2017 | +41.78% | ₹732.41 | ₹1,038.41 |
| 2016 | -31.44% | ₹1,068.21 | ₹732.41 |
| 2015 | +35.39% | ₹789.00 | ₹1,068.21 |
| 2014 | +43.01% | ₹551.71 | ₹789.00 |
| 2013 | +12.33% | ₹491.16 | ₹551.71 |
| 2012 | +43.90% | ₹341.32 | ₹491.16 |
| 2011 | +21.62% | ₹280.65 | ₹341.32 |
| 2010 | -3.69% | ₹291.39 | ₹280.65 |
| 2009 | +1.89% | ₹285.97 | ₹291.39 |
| 2008 | -28.63% | ₹400.68 | ₹285.97 |
| 2007 | +207.99% | ₹130.09 | ₹400.68 |
| 2006 | +101.70% | ₹64.50 | ₹130.09 |
| 2005 | +12.65% | ₹57.26 | ₹64.50 |
| 2004 | -12.09% | ₹65.13 | ₹57.26 |
DIVISLAB Investment Analysis: Valuation, Risk & Dividends
Key factors to consider when evaluating Divi's Laboratories Limited as an investment
Valuation
DIVISLAB currently trades at a trailing P/E ratio of 64.9, which is considered high relative to the broader market. The forward P/E of 51.9 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 10.5. The price-to-sales ratio is 15.6.
Dividends
Divi's Laboratories Limited pays a dividend to shareholders with a current yield of 0.49%. This translates to $30.00 per share annually. The payout ratio of 32% indicates sustainable dividend coverage.
Risk & Volatility
DIVISLAB has a beta of 0.12, indicating it is less volatile than the overall market. The stock's 52-week range is $4955.00 to $7071.50, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 30 analyst opinions, DIVISLAB has a consensus "hold" rating. The average price target of $6875.33 suggests 13.2% upside from current levels.
Frequently Asked Questions: DIVISLAB
What sector is DIVISLAB in? ▼
DIVISLAB operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. This sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers.
How has DIVISLAB performed historically? ▼
Over 23 years of trading history, DIVISLAB has posted gains in 17 years (74% of the time). The best year was 2007 with a +208.0% return. Past performance does not guarantee future results.
How can I invest in DIVISLAB? ▼
You can invest in DIVISLAB through any brokerage account that offers access to Indian exchanges. Popular options include commission-free brokers like Fidelity, Charles Schwab, or Robinhood (US), or international brokers like Interactive Brokers. You can buy individual shares or invest through ETFs that hold DIVISLAB.
Does DIVISLAB pay dividends? ▼
Divi's Laboratories Limited pays a dividend to shareholders with a current yield of 0.49%. This translates to $30.00 per share annually. The payout ratio of 32% indicates sustainable dividend coverage.
What does Divi's Laboratories Limited do? ▼
Divi's Laboratories Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Hyderabad, India.
What sector is DIVISLAB in? ▼
DIVISLAB operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did DIVISLAB go public? ▼
Divi's Laboratories Limited went public in 2003, making it a 23-year-old public company as of 2026.
How much would $1,000 invested in DIVISLAB 5 years ago be worth today? ▼
A $1,000 investment in DIVISLAB five years ago would be worth approximately $1,681 today, representing a 68.1% return.
Does DIVISLAB pay dividends? ▼
Yes, Divi's Laboratories Limited pays a dividend with a current yield of 0.49%, which is $30.0 per share annually.
What is DIVISLAB's market cap? ▼
Divi's Laboratories Limited has a market capitalization of $1.6 trillion, classifying it as a mega-cap company.
What is DIVISLAB's P/E ratio? ▼
DIVISLAB has a trailing P/E ratio of 64.9 and a forward P/E of 51.9, which measures how much investors are paying per dollar of earnings.
Is DIVISLAB a buy, hold, or sell? ▼
Based on 30 opinions, DIVISLAB has a consensus "hold" rating. The average price target is $6875.33.
Last updated: 3/14/2026